These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35644559)

  • 21. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
    Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y
    J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spontaneously relapsing and remitting primary CNS lymphoma in an immunocompetent 45-year-old man.
    Partap S; Spence AM
    J Neurooncol; 2006 Dec; 80(3):305-7. PubMed ID: 16794747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances and challenges in the treatment of primary central nervous system lymphoma.
    Yang H; Xun Y; Yang A; Liu F; You H
    J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolated central nervous system relapse in a patient with diffuse large B cell lymphoma.
    Sato K; Uchiyama M
    BMJ Case Rep; 2012 Jan; 2012():. PubMed ID: 22665914
    [No Abstract]   [Full Text] [Related]  

  • 25. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.
    Sung KH; Lee EH; Kim YZ
    J Korean Med Sci; 2011 Apr; 26(4):551-60. PubMed ID: 21468264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case of Primary Central Nervous System Lymphoma Arising at Site of Remote Herpes Encephalitis.
    Li V; Levine AB; Gooderham PA; Yip S; Chew J
    World Neurosurg; 2018 May; 113():217-222. PubMed ID: 29382621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study.
    Yamasaki F; Fudaba H; Asano K; Sasayama T; Natsumeda M; Shimabukuro T; Taguchi K; Koizumi S; Nakayama N; Fujii K; Nishibuchi I; Sugiyama K; Yoshida K; Yonezawa U; Yasutomo M; Kawasaki Y; Kakuta K; Katayama K; Tanaka K; Nagashima H; Tsukamoto Y; Ideguchi M; Nishizaki T; Kurozumi K; Hosoya T; Akita T; Kambe A
    BMJ Open; 2023 Apr; 13(4):e071350. PubMed ID: 37094899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment for primary CNS lymphoma: the next step.
    Abrey LE; Yahalom J; DeAngelis LM
    J Clin Oncol; 2000 Sep; 18(17):3144-50. PubMed ID: 10963643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
    Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
    J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Rare Case of Spontaneous Remission and Relapse of a Primary Central Nervous System Lymphoma.
    Ramos R; Fernandes JS; Almeida M; Almeida R
    Acta Med Port; 2018 Dec; 31(12):777-783. PubMed ID: 30684376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adrenal relapse of primary central nervous system diffuse large B-cell lymphoma: A case report.
    Ma S; Sen SS; Jug R; Zhang X; Zhang WL; Shen S; Yu CQ; Xu HT; Yang LH; Wang E
    Medicine (Baltimore); 2018 Sep; 97(38):e12482. PubMed ID: 30235749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary CNS lymphoma.
    Phillips EH; Fox CP; Cwynarski K
    Curr Hematol Malig Rep; 2014 Sep; 9(3):243-53. PubMed ID: 24969265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma.
    Chamberlain MC
    Cancer; 1994 Mar; 73(6):1728-30. PubMed ID: 8156500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary central nervous system lymphoma.
    Doucet S; Kumthekar P; Raizer J
    Curr Treat Options Oncol; 2013 Jun; 14(2):185-97. PubMed ID: 23456261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of secondary central nervous system lymphoma presenting marked hypoglycorrhachia].
    Yamashita A; Tokuda M; Matsuo M; Irie J; Tateishi Y; Mutsukura K
    Rinsho Shinkeigaku; 2019 Jun; 59(6):365-370. PubMed ID: 31142712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
    Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
    J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
    Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.